A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome
Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to demonstrate that lorcaserin has superior efficacy
compared to placebo on percent change in frequency of convulsive seizures per 28 days in
participants with Dravet syndrome.